HEPA

Hepion Pharmaceuticals Stock Price

2.14
-0.12 (-5.31%)
Upgrade to Real-Time
Afterhours (Closed)
2.14

Low
1.45

52 Week Range

High
6.18

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Hepion Pharmaceuticals Inc HEPA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -5.31% 2.14 00:00:08
Open Price Low Price High Price Close Price Prev Close
2.25 2.01 2.27 2.14 2.26
Bid Price Ask Price Spread News
2.13 3.50 1.37 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,929 4,459,899 $ 2.14 $ 9,543,435 1,922,049 1.45 - 6.18
Last Trade Time Type Quantity Stock Price Currency
19:50:07 1 $ 2.14 USD

Hepion Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 163.12M 76.23M 76.12M $ - $ - -2.23 -1.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 4.35M 1.00%

more financials information »

Hepion Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HEPA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.792.301.772.093,730,3590.3519.55%
1 Month1.55892.301.55031.882,009,7000.581137.28%
3 Months2.112.301.451.852,211,9680.031.42%
6 Months1.813.181.452.114,161,1680.3318.23%
1 Year2.306.181.452.362,707,920-0.16-6.96%
3 Years3.118.351.002.681,845,053-0.97-31.19%
5 Years3.118.351.002.681,845,053-0.97-31.19%

Hepion Pharmaceuticals Description

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.


Your Recent History
NASDAQ
HEPA
Hepion Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.